As the first Southeast Asian generic option for the originator drug Mobocertinib, the Laos Dabear version of Mobocertinib brings new hope to patients ···【Read More】
Update: 2026-06-04Source: Haiou HealthViews: 94
The Lao Daewoong version of Mobocertinib is an oral targeted drug for non-small cell lung cancer with EGFR exon 20 insertion mutation. It is a high-qu···【Read More】
Update: 2026-06-04Source: Haiou HealthViews: 92
In the global pharmaceutical landscape where innovative drugs and generics coexist, the Lao Big Bear version of Acalabrutinib, with its strict quality···【Read More】
Update: 2026-06-04Source: Haiou HealthViews: 94
As an important generic version of the Bruton's tyrosine kinase (BTK) inhibitor, the Laos Dabear version of Acalabrutinib is helping more patients···【Read More】
Update: 2026-06-04Source: Haiou HealthViews: 98
The acalabrutinib generic version launched by Lao Bear Pharmaceutical provides cancer patients worldwide with a new cost-effective treatment option be···【Read More】
Update: 2026-06-04Source: Haiou HealthViews: 87
For patients who require long-term use of Upadacitinib to control conditions such as rheumatoid arthritis and atopic dermatitis, the generic version l···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 92
In the field of autoimmune disease drugs, the Dabear version of Upadacitinib from Laos is gradually becoming a new hope for patients in low- and middl···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 98
Upadacitinib produced by Lao Big Bear Pharmaceutical Company, as a legal generic version of the originator upadacitinib, provides a more cost-controll···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 98
Against the backdrop of increasing challenges in access to innovative drugs, the Laos Dabear version of Sotorasib, with its active ingredients highly ···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 92
In recent years, the quietly emerged Lao Big Bear version of Sotorasib, an affordable alternative to this targeted therapy for refractory KRAS G12C mu···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 89
The Laotian Bear version of Sotorasib, as the first generic version of the world's first approved KRAS G12C inhibitor original drug, is produced b···【Read More】
Update: 2026-06-03Source: Haiou HealthViews: 89
In today's context of increasing attention to targeted anti-tumor drugs, the Laos Dabear version of Encorafenib, with its compliant production bac···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 98
As one of the first generic versions of the original drug Encorafenib, the Lao Big Bear version of Encorafenib, with proven equivalence and significan···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 96
The generic version of Encorafenib launched by Lao Big Bear Pharmaceutical provides a more accessible option for patients worldwide who need BRAF inhi···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 98
The Laos Daxiong version of Axitinib strictly adheres to international generic drug production standards, providing clinicians and patients with a val···【Read More】
Update: 2026-06-02Source: Haiou HealthViews: 93
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos